Accumulation and therapeutic modulation of 6-sulfo LacNAc+ dendritic cells in multiple sclerosis

Neurology: Neuroimmunology and NeuroInflammation

Volumn 1, Issue 3, 2014, Pages

  Thomas, Katja ^a   Dietze, Kristin ^b   Wehner, Rebekka ^b   Metz, Imke ^c   Tumani, Hayrettin ^a   Schultheiß, Thorsten ^a   Günther, Claudia ^a   Schäkel, Knut ^e   Reichmann, Heinz ^a,d   Brück, Wolfgang ^c   Schmitz, Marc ^b,f   Ziemssen, Tjalf ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 SULFO LACNAC; BETA INTERFERON; CD150 ANTIGEN; GLATIRAMER; METHYLPREDNISOLONE; NATALIZUMAB; P SELECTIN GLYCOPROTEIN LIGAND 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BRAIN BIOPSY; BRAIN DAMAGE; CD3+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CEREBROSPINAL FLUID; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMYELINATION; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOGENESIS; IN VITRO STUDY; MONOCYTE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 84931569859     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000033     Document Type: Article

References (42)

1. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 2009;9:393-407.
2. Mars LT, Saikali P, Liblau RS, Arbour N. Contribution of CD8 T lymphocytes to the immuno-pathogenesis of multiple sclerosis and its animal models. Biochim Biophys Acta 2011;1812:151-161.
3. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007;449:419-426.
4. Comabella M, Montalban X, Münz C, Lünemann JD. Targeting dendritic cells to treat multiple sclerosis. Nat Rev Neurol 2010;6:499-507.
5. Zozulya AL, Clarkson BD, Ortler S, Fabry Z, Wiendl H. The role of dendritic cells in CNS autoimmunity. J Mol Med (Berl) 2010;88:535-544.
6. Nuyts AH, Lee WP, Bashir-Dar R, Berneman ZN, Cools N. Dendritic cells in multiple sclerosis: key players in the immunopathogenesis, key players for new cellular immunotherapies. Mult Scler 2013;19:995-1002.
7. Greter M, Heppner FL, Lemos MP, et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 2005;11:328-334.
8. Bailey SL, Schreiner B, McMahon EJ, Miller SD. CNS myeloid DCs presenting endogenous myelin peptides preferentially polarize CD4+ TH-17 cells in relapsing EAE. Nat Immunol 2007;8:172-180.
9. Ji Q, Castelli L, Goverman JM. MHC class I-restricted myelin epitopes are cross-presented by Tip-DCs that promote determinant spreading to CD8+ T cells. Nat Immunol 2013;14:254-261.
10. Zozulya AL, Ortler S, Lee JE, et al. Intracerebral dendritic cells critically modulate encephalitogenic versus regulatory immune responses in the CNS. J Neurosci 2009;29:140-152.
11. Schäkel K, Mayer E, Federle C, Schmitz M, Riethmüller G, Rieber EP. A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur J Immunol 1998;28:4084-4093.
12. Schäkel K, Kannagi R, Kniep B, et al. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity 2002;17:289-301.
13. Schäkel K, Von Kietzell M, Hänsel A, et al. Human 6-sulfo LacNAc-expressing dendritic cells are principal producers of early interleukin-12 and are controlled by erythrocytes. Immunity 2006;24:767-777.
14. Hänsel A, Günther C, Ingwersen J, et al. Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong Th17/Th1 T-cell responses. J Allergy Clin Immunol 2011;127: 787-794.
15. Döbel T, Kunze A, Babatz J, et al. FcgRIII equips immature 6-sulfo LacNAc-expressing dendritic cells (slanDCs) with a unique capacity to handle IgG-complexed antigens. Blood 2013;121:3609-3618.
16. Schmitz M, Zhao S, Schäkel K, Bornhäuser M, Ockert D, Rieber EP. Native human blood dendritic cells as potent effectors in antibody-dependent cellular cytotoxicity. Blood 2002;100:1502-1504.
17. Schmitz M, Zhao S, Deuse Y, et al. Tumoricidal potential of native blood dendritic cells: direct tumor cell killing and activation of NK cell-mediated cytotoxicity. J Immunol 2005;174:4127-4134.
18. Wehner R, Löbel B, Bornhäuser M, et al. Reciprocal activating interaction between 6-sulfo LacNAc+ dendritic cells and NK cells. Int J Cancer 2009;124:358-366.
19. Hänsel A, Günther C, Baran W, et al. Human 6-sulfo LacNAc (slan) dendritic cells have molecular and functional features of an important pro-inflammatory cell type in lupus erythematosus. J Autoimmun 2013;40:1-8.
20. Günther C, Blau K, Förster U, Viehweg A, Wozel G, Schäkel K. Reduction of inflammatory slan (6-sulfo LacNAc) dendritic cells in psoriatic skin of patients treated with etanercept. Exp Dermatol 2013;22:535-540.
21. Lucchinetti CF, Brück W, Rodriguez M, Lassmann H. Multiple sclerosis: lessons from neuropathology. Semin Neurol 1998;18:337-349.
22. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
23. Vass K, Lassmann H, Wekerle H, Wisniewski HM. The distribution of Ia antigen in the lesions of rat acute experimental allergic encephalomyelitis. Acta Neuropathol 1986;70:149-160.
24. Lucchinetti CF, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-717.
25. Plumb J, Armstrong MA, Duddy M, Scheithauer B, Rodriguez M, Lassmann H. CD83-positive dendritic cells are present in occasional perivascular cuffs in multiple sclerosis lesions. Mult Scler 2003;9:142-147.
26. Li Y, Chu N, Hu A, Gran B, Rostami A, Zhang GX. Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia. Brain 2007;130:490-501.
27. Serafini B, Rosicarelli B, Magliozzi R, et al. Dendritic cells in multiple sclerosis: maturation stage, myelin uptake, and interaction with proliferating T cells. J Neuropathol Exp Neurol 2006;65:124-141.
28. Ifergan I, Kebir H, Bernard M, et al. The blood-brain barrier induces differentiation of migrating monocytes into TH17-polarizing dendritic cells. Brain 2008;131:785-799.
29. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008;8:594-606.
30. Lande R, Gafa V, Serafini B, et al. Plasmacytoid dendritic cells in multiple sclerosis: intracerebral recruitment and impaired maturation in response to interferon-b. J Neuropathol Exp Neurol 2008;67:388-401.
31. Ambrosini E, Remoli ME, Giacomini E, et al. Astrocytes produce dendritic cell-attracting chemokines in vitro and in multiple sclerosis lesions. J Neuropathol Exp Neurol 2005;64:706-715.
32. Calderon TM, Eugenin EA, Lopez L, et al. A role for CXCL12 (SDF-1a) in the pathogenesis of multiple sclerosis: regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. J Neuroimmunol 2006;177:27-39.
33. Krumbholz M, Theil D, Cepok S, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006;129:200-211.
34. Pashenkov M, Huang YM, Kostulas V, Haglund M, Söderström M, Link H. Two subsets of dendritic cells are present in human cerebrospinal fluid. Brain 2001; 124:480-492.
35. Longhini AL, Von Glehn F, Brandao CO, et al. Plasmacytoid dendritic cells are increased in cerebrospinal fluid of untreated patients during multiple sclerosis relapse. J Neuroinflammation 2011;8:2.
36. Navarro J, Aristimuno C, Sánchez-Ramón S, et al. Circulating dendritic cell subsets and regulatory T cells at multiple sclerosis relapse: different short-term changes on corticoste-roids therapy. J Neuroimmunol 2006;176:153-161.
37. Abe M, Thompson AW. Dexamethasone preferentially suppresses plasmacytoid dendritic cell differentiation and enhances their apoptotic death. Clin Immunol 2006;118:300-306.
38. Piemonti L, Monti P, Allavena P, Leone BE, Caputo A, Di Carlo V. Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol 1999;162: 6473-6481.
39. Rozkova D, Horvarth R, Bartunkova J, Spisek R. Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. Clin Immunol 2006;120: 260-271.
40. Yen JH, Ganea D. Interferon beta induces mature dendritic cell apoptosis through caspase-11/caspase-3 activation. Blood 2009;114:1344-1354.
41. Lòpez C, Comabella M, Al-zayaz H, Tintoré M, Montalban X. Altered maturation of circulating dendritic cells in primary progressive MS patients. J Neuroimmunol 2006;175:183-191.
42. Balashov KE, Aung LL, Vaknin-Dembinsky A, Dhib-Jalbut S, Weiner HL. Interferon-b inhibits toll-like receptor 9 processing in multiple sclerosis. Ann Neurol 2010;68:899-906.